Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.
PYC Therapeutics has applied for quotation on the ASX of 250,000 new ordinary fully paid shares, with an issue date of April 28, 2026. The additional securities, arising from the exercise or conversion of existing instruments, will modestly expand the company’s listed capital base and may provide incremental funding flexibility as it advances its therapeutic programs.
The move reflects ongoing corporate activity typical of early- to mid-stage biotech issuers that periodically increase their quoted share count. While the size of this issuance is limited, it signals continued engagement with capital markets and may slightly dilute existing shareholders while supporting operational or strategic needs within PYC’s development pipeline.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.84 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code PYC. The company operates in the therapeutics sector, focusing on the development of medical treatments and related technologies for healthcare markets.
Average Trading Volume: 1,507,284
Technical Sentiment Signal: Buy
Current Market Cap: A$1.27B
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.